Patent intelligence · US
US 8124120
Crosslinked hyaluronic acid compositions for tissue augmentation
Crosslinked hyaluronic acid compositions for tissue augmentation
Patent details — US 8124120
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 28, 2012
- Expiration
- Feb 23, 2032
- Applicant
- ANIKA THERAPEUTICS, INC.
- Claims
- 11
- CPC classes
- A61K, A61K31/24, A61K47/36, A61K9/0019
Quick answer
US 8124120 (Crosslinked hyaluronic acid compositions for tissue augmentation) is held by ANIKA THERAPEUTICS, INC.. Status: granted. Granted Feb 28, 2012. Expires Feb 23, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ANIKA THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/24, A61K47/36, A61K9/0019, A61K9/0021, A61K9/0024
More from ANIKA THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12415779
Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
granted -
US 12391642
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12331026
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
granted -
US 12264167
Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
granted -
US 12171741
2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12077506
Indane derivatives as hypoxia inducible factor-2(α) inhibitors
granted -
US 11939303
Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
granted -
US 11753366
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted
Frequently asked questions
What is US patent 8124120?
US 8124120 (Crosslinked hyaluronic acid compositions for tissue augmentation) is held by ANIKA THERAPEUTICS, INC.. Status: granted. Granted Feb 28, 2012. Expires Feb 23, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8124120?
ANIKA THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 8124120 expire?
Our index shows an expiration date of Feb 23, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.